# Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

> **NCT05361057** · PHASE2 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Measurable Disease

## Interventions

- **DRUG:** Venetoclax, Azacitidine
- **DRUG:** Venetoclax, daunorubicin, cytarabine

## Key facts

- **NCT ID:** NCT05361057
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-29
- **Primary completion:** 2023-02-28
- **Final completion:** 2024-01-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The research center has conducted a more comprehensive study.
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361057, "Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05361057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*